Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation

References

• Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217–251.
   PubMed Web of Science ®Google Scholar
• Biassoni R, Cantoni C, Falco M, et al. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med. 1996;183(2):645–650.
   PubMed Web of Science ®Google Scholar
• Lanier LL, Corliss BC, Wu J, et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391(6668):703–707.
   PubMed Web of Science ®Google Scholar
• Hsu KC, Liu XR, Selvakumar A, et al. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol. 2002;169(9):5118–5129.
   PubMed Web of Science ®Google Scholar
• Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology. 2010;129(1):8–19.
   PubMed Web of Science ®Google Scholar
• Robinson J, Halliwell JA, McWilliam H, et al. IPD–the immuno polymorphism database. Nucleic Acids Res. 2013;41(Database issue):D1234–1240.
   PubMedGoogle Scholar
• Manser AR, Weinhold S, Uhrberg M. Human KIR repertoires: shaped by genetic diversity and evolution. Immunol Rev. 2015;267(1):178–196.
   PubMed Web of Science ®Google Scholar
• Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100(6):1935–1947.
   PubMed Web of Science ®Google Scholar
• Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106(13):4370–4376.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333–339.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100.
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814–819.
   PubMed Web of Science ®Google Scholar
• Mancusi A, Ruggeri L, Urbani E, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood. 2015;125(20):3173–3182.
   PubMed Web of Science ®Google Scholar
• Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726–732.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411–2419.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Cooley S, Wang T, et al. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020;4(4):740–754.
   PubMed Web of Science ®Google Scholar
• Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006;82(8):1024–1030.
   PubMed Web of Science ®Google Scholar
• McQueen KL, Dorighi KM, Guethlein LA, et al. Donor-recipient combinations of group a and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol. 2007;68(5):309–323.
   PubMed Web of Science ®Google Scholar
• Verheyden S, Schots R, Duquet W, et al. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005;19(8):1446–1451.
   PubMed Web of Science ®Google Scholar
• Clausen J, Wolf D, Petzer AL, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol. 2007;148(3):520–528.
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367(9):805–816.
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol. 2014;192(10):4592–4600.
   PubMed Web of Science ®Google Scholar
• Sobecks RM, Wang T, Askar M, et al. Impact of KIR and HLA genotypes on outcomes after reduced-intensity conditioning hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(9):1589–1596.
   PubMed Web of Science ®Google Scholar
• Dhuyser A, Aarnink A, Peres M, et al. KIR in allogeneic hematopoietic stem cell transplantation: need for a unified paradigm for donor selection. Front Immunol. 2022;13:821533.
   PubMedGoogle Scholar
• Yu N, Askar M, Wadsworth K, et al. Current HLA testing recommendations to support HCT. Hum Immunol 2022;83(10):665–673, (PMID: 35798627).
   Google Scholar
• Schetelig J, Baldauf H, Koster L, et al. Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Front Immunol. 2020;11:584520.
   PubMed Web of Science ®Google Scholar
• Moyer AM, Hashmi SK, Kroning CM, et al. Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. Eur J Haematol. 2017;99(3):275–282.
   PubMed Web of Science ®Google Scholar
• Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924–934.
   PubMedGoogle Scholar
• Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101(9):1835–1842.
   PubMed Web of Science ®Google Scholar
• Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507.
   PubMed Web of Science ®Google Scholar
• Olson JA, Leveson-Gower DB, Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293–4301.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Cooley S, Wang T, participating center writing committee, et al. KIR donor selection: feasibility in identifying better donors. Biol Blood Marrow Transplant. 2019;25(1):e28–e32.
   PubMedGoogle Scholar
• Bultitude WP, Schellekens J, Szydlo RM, et al. Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. Bone Marrow Transplant. 2020;55(10):1975–1984.
   PubMed Web of Science ®Google Scholar